LONDON, March 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Galena Biopharma Inc. (NASDAQ: GALE), Alkermes PLC (NASDAQ: ALKS), Seattle Genetics Inc. (NASDAQ: SGEN), and CorMedix Inc. (NYSE MKT: CRMD). Free research report on Exact Sciences can be accessed at http://get.Investor-Edge.com/pdf/?c=Exact%20Sciences&d=26-Mar-2015&s=EXAS. On Wednesday, March 25, 2015, the NASDAQ Composite ended at 4,876.52, down 2.37%, the Dow Jones Industrial Average declined 1.62%, to finish the day at 17,718.54, and the S&P 500 closed at 2,061.05, down 1.46%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 840.82, down 1.84%, while the index has advanced 5.77% in the last three months. Register for your complimentary reports at the links given below.

On Wednesday, shares in Exact Sciences Corp. fluctuated between $22.50 and $23.37 before ending the session 0.99% lower at $23.06. The stock reported a trading volume of 1.33 million shares, below its three months average volume of 1.69 million shares. Exact Sciences Corp.'s shares have declined 4.63% in the previous three trading sessions and 4.00% in the last one month. However, the stock has surged 61.82% in the past one year. The company's shares are trading above its 200-day moving averages of $22.13. Moreover, shares of Exact Sciences Corp. have a Relative Strength Index (RSI) of 43.14. Sign up and read the free notes on EXAS at:

http://get.Investor-Edge.com/pdf/?c=Exact%20Sciences&d=26-Mar-2015&s=EXAS

Galena Biopharma Inc.'s stock lost 4.41%, to close the day at an intra-day low of $1.41. The stock recorded a trading volume of 3.18 million shares, above its three months average volume of 2.36 million shares. The stock oscillated between $1.41 and $1.50 during the session. Over the last three trading sessions and over the past three months, Galena Biopharma Inc.'s shares have declined 3.42% and 5.37%, respectively. Further, the stock has lost 45.56% in the past one year. The company's shares are trading below their 50-day and 200-day moving averages. The stock's 200-day moving average of $2.11 is above its 50-day moving average of $1.70. Additionally, Galena Biopharma Inc. has an RSI of 38.61. The complimentary notes on GALE can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Galena%20Biopharma&d=26-Mar-2015&s=GALE

On Wednesday, shares in Alkermes PLC recorded a trading volume of 1.52 million shares which was at par with its three months average volume. The stock ended the day at $62.46, which was 5.76% below its previous day's closing of $66.28, and registered an intraday range of $62.41 and $66.89. Although Alkermes PLC's shares have lost 7.05% in the previous three trading sessions, it has advanced 11.22% in the last three months and 42.90% in the past one year. The stock is trading above its 200-day moving average of $53.83. Furthermore, shares of Alkermes PLC have an RSI of 42.65. Register for free on Investor-Edge and access the latest research on ALKS at:

http://get.Investor-Edge.com/pdf/?c=Alkermes&d=26-Mar-2015&s=ALKS

Seattle Genetics Inc.'s stock plummeted 6.63%, to close Wednesday's session at $35.19, after oscillating between $34.85 and $37.85. The stock recorded a trading volume of 1.50 million shares, above its three months average volume of 1.20 million shares. Over the last one month and the previous year, Seattle Genetics Inc.'s shares have declined 3.93% and 25.08%, respectively. However, the stock has gained 13.15% in the last three months. The company's shares are trading above their 50-day moving average. The stock's 200-day moving average of $36.43 is above its 50-day moving average of $34.21. Further, Seattle Genetics Inc.'s stock has an RSI of 56.97. The complete research on SGEN is available for free at:

http://get.Investor-Edge.com/pdf/?c=Seattle%20Genetics&d=26-Mar-2015&s=SGEN

CorMedix Inc.'s stock finished Wednesday's session flat at $7.45. A total of 0.65 million shares were traded, which was below its three months average volume of 0.82 million shares. The stock moved between $7.24 and $7.57 during the session. CorMedix Inc.'s shares have rallied 43.27% in the last one month and 380.34% in the previous three months. Additionally, the stock has surged 183.27% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $4.72 is greater than its 200-day moving average of $2.49. CorMedix Inc.'s stock has an RSI of 58.29. Free in depth research on CRMD is available at:

http://get.Investor-Edge.com/pdf/?c=CorMedix&d=26-Mar-2015&s=CRMD

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge